Prognostic impact of interhospital variation in adjuvant chemotherapy for patients with Stage II/III colorectal cancer: a nationwide study

Colorectal Disease

Volumn 20, Issue 7, 2018, Pages O162-O172

  Arakawa, K ^a   Kawai, K ^a   Tanaka, T ^a   Hata, K ^a   Sugihara, K ^b   Nozawa, H ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

adjuvant chemotherapy; colorectal cancer; Interhospital variation

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CARBOHYDRATE ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; FOLINIC ACID; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; UFT;

ADJUVANT THERAPY; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER STAGING; CHILD; COLORECTAL CANCER; CONFIDENCE INTERVAL; FEMALE; HAZARD RATIO; HUMAN; HUMAN TISSUE; INFANT; JAPAN; LYMPH NODE; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; VERY ELDERLY; ADJUVANT CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL TUMOR; EVALUATION STUDY; HOSPITAL; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PROGNOSIS; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; FEMALE; HOSPITALS; HUMANS; JAPAN; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 85049535140     PISSN: 14628910     EISSN: 14631318     Source Type: Journal    
DOI: 10.1111/codi.14260     Document Type: Article

References (31)

1. Center MM, Jemal A, Ward E. International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev 2009; 18: 1688–94.
2. Lin J, Qiu M, Xu R, Dobs AS. Comparison of survival and clinicopathologic features in colorectal cancer among African American, Caucasian, and Chinese patients treated in the United States: results from the surveillance epidemiology and end results (SEER) database. Oncotarget 2015; 6: 33935–43.
3. QUASAR Collaborative Group. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007; 370: 2020–9.
4. Labianca R, Marsoni S, Pancera G, Torri V. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 1995; 345: 939–44.
5. Mamounas E, Wieand S, Wolmark N et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 1999; 17: 1349–55.
6. Benson AB III, Schrag D, Somerfield MR et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004; 22: 3408–19.
7. Moertel CG, Fleming TR, Macdonald JS et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322: 352–8.
8. O'Connell MJ, Laurie JA, Kahn M et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 1998; 16: 295–300.
9. Benson AB III, Venook AP, Cederquist L et al. Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2017; 15: 370–98.
10. Schmoll HJ, Van Cutsem E, Stein A et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 2012; 23: 2479–516.
11. Alter E, Phelip JM, Guilhot JN, Matysiak M, Vermorel M, Roblin X. Adjuvant chemotherapy for stage II colon cancer: influence of care structures' characteristics on a controversial clinical practice. Eur J Gastroenterol Hepatol 2007; 19: 995–1001.
12. Kumar A, Kennecke HF, Renouf DJ et al. Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer. Cancer 2015; 121: 527–34.
13. Upadhyay S, Dahal S, Bhatt VR, Khanal N, Silberstein PT. Chemotherapy use in stage III colon cancer: a National Cancer Database analysis. Ther Adv Med Oncol 2015; 7: 244–51.
14. Morris M, Platell C, Fritschi L, Iacopetta B. Failure to complete adjuvant chemotherapy is associated with adverse survival in stage III colon cancer patients. Br J Cancer 2007; 96: 701–7.
15. Becerra AZ, Probst CP, Tejani MA et al. Opportunity lost: adjuvant chemotherapy in patients with stage III colon cancer remains underused. Surgery 2015; 158: 692–9.
16. Daly MC, Hanseman DJ, Abbott DE, Shah SA, Paquette IM. Hospital variability in use of adjuvant chemotherapy for patients with stage 2 and 3 colon cancer. Dis Colon Rectum 2016; 59: 1134–41.
17. Chagpar R, Xing Y, Chiang YJ et al. Adherence to stage-specific treatment guidelines for patients with colon cancer. J Clin Oncol 2012; 30: 972–9.
18. Schrag D, Cramer LD, Bach PB, Cohen AM, Warren JL, Begg CB. Influence of hospital procedure volume on outcomes following surgery for colon cancer. JAMA 2000; 284: 3028–35.
19. Watanabe T, Itabashi M, Shimada Y et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. Int J Clin Oncol 2012; 17: 1–29.
20. André T, Sargent D, Tabernero J et al. Current issues in adjuvant treatment of stage II colon cancer. Ann Surg Oncol 2006; 13: 887–98.
21. Jessup JM, Stewart A, Greene FL, Minsky BD. Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation. JAMA 2005; 294: 2703–11.
22. Boland GM, Chang GJ, Haynes AB et al. Association between adherence to National Comprehensive Cancer Network treatment guidelines and improved survival in patients with colon cancer. Cancer 2013; 119: 1593–601.
23. Schrag D, Cramer LD, Bach PB, Begg CB. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst 2001; 93: 850–7.
24. Oliver JS, Martin MY, Richardson L, Kim Y, Pisu M. Gender differences in colon cancer treatment. J Womens Health 2013; 22: 344–51.
25. Ishiguro M, Higashi T, Watanabe T, Sugihara K. Changes in colorectal cancer care in Japan before and after guideline publication: a nationwide survey about D3 lymph node dissection and adjuvant chemotherapy. J Am Coll Surg 2014; 218: 969–77.
26. Wolmark N, Fisher B, Rockette H et al. Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-011. J Natl Cancer Inst 1988; 80: 30–6.
27. Bos AC, van Erning FN, Elferink MA et al. No Difference in Overall Survival Between Hospital Volumes for Patients With Colorectal Cancer in The Netherlands. Dis Colon Rectum 2016; 59: 943–52.
28. Kotake K, Mizuguchi T, Moritani K et al. Impact of D3 lymph node dissection on survival for patients with T3 and T4 colon cancer. Int J Colorectal Dis 2014; 29: 847–52.
29. Hsiao FY, Mullins CD, Onukwugba E, Pandya N, Hanna N. Comparative effectiveness of different chemotherapeutic regimens on survival of people aged 66 and older with stage III colon cancer: a “real world” analysis using surveillance, epidemiology, and end results-medicare data. J Am Geriatr Soc 2011; 59: 1717–23.
30. Aspinall SL, Good CB, Zhao X et al. Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans. BMC Cancer 2015; 15: 62.
31. Neugut AI, Matasar M, Wang X et al. Duration of adjuvant chemotherapy for colon cancer and survival among the elderly. J Clin Oncol 2006; 24: 2368–75.